Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term Sulfonylurea Response in KCNJ11 Neonatal Diabetes
NCT02624817Phase 4Completed
- Sponsor
- Haukeland University Hospital
- Start
- Dec 2015
- Primary completion
- Aug 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of glibenclamide in Permanent neonatal diabetes mellitus (PNDM), sponsored by Haukeland University Hospital. Primary endpoints: Sulfonylurea efficacy at 13 years and Metabolic control at 13 years. Started Dec 2015; status: completed.
02
Drugs
glibenclamide
03
Conditions
Permanent neonatal diabetes mellitus (PNDM)
Beyond the preview
Go deeper on NCT02624817.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02624817.